EUVIMEDEUVIMED entdecken
Crossref

Targeting PKM2 by (+)-homocrepidine A restrains glycolytic reprogramming and reshapes macrophage fate to alleviate acute lung injury

Rongrong Dong, Yu Yang, Na Luo, Tingting Wang, Yuxuan Qiu, Wenlong Qin, Jinque Luo, Jianming Cheng, Yinan Zhang, Yang Hu

Biochemical Pharmacology · 2026

DOI: 10.1016/j.bcp.2026.118404 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026. Verfasst von Rongrong Dong und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory on Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacture, Nanjing University of Chinese M…. Hauptthemen laut MEDLINE: Acute Lung Injury, Glycolysis, Pyruvate Kinase, Carrier Proteins. Die Arbeit nennt 45 Literaturangaben. Gefördert von: Major Basic Research Project of the Natural Science Foundation of the Jiangsu Higher Education Institutions, National Natural Science Foundation of China, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alveolar macrophages represent a critical immune population that rapidly senses excessive inflammatory stimuli and contributes substantially to the development of acute lung injury (ALI). Dendrobium crepidatum is a medicinal herb traditionally used for respiratory disorders; however, its protective effects against ALI and the underlying mechanisms remain unclear. Here, we identified homocrepidine A (HCA), a high-abundance alkaloid from D. crepidatum, as an active compound that ameliorates lipopolysaccharide (LPS)-induced ALI in mice, with the natural enantiomer (+)-HCA displaying superior anti-ALI activity. (+)-HCA effectively redirected alveolar macrophage polarization away from a pro-inflammatory M1 state toward an inflammation-resolving M2 phenotype. Mechanistically, pyruvate kinase M2 (PKM2) was identified as the direct molecular target of (+)-HCA. Furthermore, (+)-HCA directly bound to PKM2 at His78, inhibited Tyr105 phosphorylation, promoted tetramer formation and restrained the formation of nuclear-localized dimeric PKM2. Functionally, genetic depletion of PKM2 or disruption of the His78-dependent interaction markedly weakened the ability of (+)-HCA to remodel macrophage glycolytic metabolism, suppress M1 macrophage polarization, and alleviate ALI progression. Collectively, this study identifies (+)-HCA as the bioactive enantiomer responsible for the anti-ALI activity of HCA and demonstrates that PKM2-mediated immunometabolic reprogramming underlies its protective effects. These findings establish PKM2 as a promising therapeutic target and (+)-HCA as a potential lead compound for ALI treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Lung InjuryGlycolysisPyruvate KinaseCarrier ProteinsMacrophages, AlveolarThyroid HormonesMacrophagesMembrane ProteinsAnimalsMiceMaleMice, Inbred C57BLHumansMetabolic ReprogrammingThyroid Hormone-Binding ProteinsLipopolysaccharidesPyridazinesPyrroles

Stichwörter der Autor:innen

(+)-HCAAcute lung injuryGlycolysisMacrophage polarizationPKM2

Substanzen

Pyruvate KinaseCarrier ProteinsPkm protein, mouseThyroid Hormone-Binding ProteinsThyroid HormonesLipopolysaccharidesML-265Membrane ProteinsPyridazinesPyrroles

Autor:innen und Institutionen

  • State Key Laboratory on Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacture, Nanjing University of Chinese Medicine, Nanjing 210023, China.
  • State Key Laboratory on Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacture, Nanjing University of Chinese Medicine, Nanjing 210023, China; Jiangsu Province Engineering Research…
  • Hunan Provincial Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, College of Pharmacy, Changsha Medical University, Changsha 410219, China.
  • State Key Laboratory on Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacture, Nanjing University of Chinese Medicine, Nanjing 210023, China. Electronic address: yinanzhang@njucm.e…

Förderung

  • Major Basic Research Project of the Natural Science Foundation of the Jiangsu Higher Education Institutions
  • National Natural Science Foundation of China
  • National Key Research and Development Program of China

Zitieren

APA

Dong, R., Yang, Y., Luo, N., Wang, T., Qiu, Y., Qin, W., Luo, J., Cheng, J., Zhang, Y., & Hu, Y. (2026). Targeting PKM2 by (+)-homocrepidine A restrains glycolytic reprogramming and reshapes macrophage fate to alleviate acute lung injury. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2026.118404

Vancouver

Dong R, Yang Y, Luo N, Wang T, Qiu Y, Qin W, et al. Targeting PKM2 by (+)-homocrepidine A restrains glycolytic reprogramming and reshapes macrophage fate to alleviate acute lung injury. Biochemical Pharmacology. 2026. doi:10.1016/j.bcp.2026.118404

BibTeX
@article{Dong2026,
  author = {Dong, Rongrong and Yang, Yu and Luo, Na and Wang, Tingting and Qiu, Yuxuan and Qin, Wenlong and Luo, Jinque and Cheng, Jianming and Zhang, Yinan and Hu, Yang},
  title = {Targeting PKM2 by (+)-homocrepidine A restrains glycolytic reprogramming and reshapes macrophage fate to alleviate acute lung injury},
  journal = {Biochemical Pharmacology},
  year = {2026},
  doi = {10.1016/j.bcp.2026.118404}
}
Kostenlos starten →